CRBU · Insider Trading
Caribou Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by CRBU officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | Timothy P Kelly | Chief Technology Officer | Sell | −6,228 | −$12.02K |
| 2026-02-24 | Ruhi Ahmad Khan | Chief Business Officer | MIXED | +38,062 | −$13.60K |
| 2026-02-24 | Tina M. Albertson | Chief Medical Officer | MIXED | +53,934 | −$2.09K |
| 2026-02-24 | Barbara G McClung | Chief Legal Officer | MIXED | +38,062 | −$13.60K |
| 2026-02-24 | Timothy P Kelly | Chief Technology Officer | MIXED | +41,853 | −$6.17K |
| 2026-02-20 | Dara Richardson-Heron | Director | A | +45,000 deriv. | — |
| 2026-02-20 | Natalie Sacks | Director | A | +45,000 deriv. | — |
| 2026-02-20 | David Lee Johnson | Director | A | +45,000 deriv. | — |
| 2026-02-20 | Nancy Whiting | Director | A | +45,000 deriv. | — |
| 2026-02-20 | Ran Zheng | Director | A | +45,000 deriv. | — |
| 2026-02-20 | Andrew Guggenhime | Director | A | +45,000 deriv. | — |
| 2026-02-20 | Scott Braunstein | Director | A | +45,000 deriv. | — |
| 2026-02-20 | Rachel E. Haurwitz | President and CEO | A | +151,700 | — |
| 2026-02-20 | Sriram Ryali | Chief Financial Officer | A | +55,000 | — |
| 2025-03-17 | Rachel E. Haurwitz | President and CEO | Buy | +20,000 | +$20.40K |
| 2025-02-21 | Natalie Sacks | Director | A | +40,500 deriv. | — |
| 2025-02-21 | Andrew Guggenhime | Director | A | +40,500 deriv. | — |
| 2025-02-21 | Ruhi Ahmad Khan | Chief Business Officer | MIXED | +33,936 | −$4.81K |
| 2025-02-21 | Scott Braunstein | Director | A | +40,500 deriv. | — |
| 2025-02-21 | Tina M. Albertson | Chief Medical Officer | A | +14,589 | — |
| 2025-02-21 | Barbara G McClung | Chief Legal Officer | MIXED | +33,936 | −$4.81K |
| 2025-02-21 | Rachel E. Haurwitz | President and CEO | A | +136,750 | — |
| 2025-02-21 | Dara Richardson-Heron | Director | A | +40,500 deriv. | — |
| 2025-02-21 | Nancy Whiting | Director | A | +40,500 deriv. | — |
| 2025-02-21 | Steven Kanner | Chief Scientific Officer | MIXED | +33,936 | −$4.81K |
| 2025-02-21 | Timothy P Kelly | Chief Technology Officer | A | +37,500 | — |
| 2025-02-21 | David Lee Johnson | Director | A | +40,500 deriv. | — |
| 2025-02-21 | Ran Zheng | Director | A | +40,500 deriv. | — |
| 2025-01-30 | Sriram Ryali | Chief Financial Officer | Buy | +17,360 | +$24.65K |
| 2025-01-10 | Sriram Ryali | Chief Financial Officer | A | +300,000 deriv. | — |
| 2024-11-22 | Ryan Fischesser | VP of Finance and Controller | A | +25,000 | — |
| 2024-08-20 | Tina M. Albertson | Chief Medical Officer | A | +300,000 deriv. | — |
| 2024-02-22 | Nancy Whiting | Director | A | +39,500 deriv. | — |
| 2024-02-22 | Andrew Guggenhime | Director | A | +39,500 deriv. | — |
| 2024-02-22 | Ran Zheng | Director | A | +39,500 deriv. | — |
| 2024-02-22 | Barbara G McClung | Chief Legal Officer | A | +33,000 | — |
| 2024-02-22 | Jason O'Byrne | Chief Financial Officer | A | +33,000 | — |
| 2024-02-22 | Steven Kanner | Chief Scientific Officer | A | +33,000 | — |
| 2024-02-22 | Natalie Sacks | Director | A | +39,500 deriv. | — |
| 2024-02-22 | Ruhi Ahmad Khan | Chief Business Officer | A | +33,000 | — |
| 2024-02-22 | Dara Richardson-Heron | Director | A | +39,500 deriv. | — |
| 2024-02-22 | Rachel E. Haurwitz | President and CEO | A | +118,700 | — |
| 2024-02-22 | Scott Braunstein | Director | A | +39,500 deriv. | — |
| 2024-02-22 | David Lee Johnson | Director | A | +39,500 deriv. | — |
| 2024-02-08 | Steven Kanner | Chief Scientific Officer | M | +30,577 | +$82.25K |
| 2024-01-09 | Timothy P Kelly | Chief Technology Officer | A | +300,000 deriv. | — |
| 2023-06-09 | Rachel E. Haurwitz | President and CEO | M | +10,000 | +$29.60K |
| 2023-03-22 | Rachel E. Haurwitz | President and CEO | M | +10,000 | +$29.60K |
| 2023-02-23 | Dara Richardson-Heron | Director | A | +21,500 deriv. | — |
| 2023-02-23 | Scott Braunstein | Director | A | +21,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rachel E. Haurwitz | President and CEO | 3,816,545 | $1.59M |
| Barbara G McClung | Chief Legal Officer | 481,564 | $199.99K |
| Steven Kanner | Chief Scientific Officer | 431,556 | $179.23K |
| Ryan Fischesser | VP of Finance and Controller | 118,854 | $49.36K |
| Ruhi Ahmad Khan | Chief Business Officer | 111,936 | $46.49K |
| Timothy P Kelly | Chief Technology Officer | 73,125 | $30.37K |
| Sriram Ryali | Chief Financial Officer | 72,360 | $30.05K |
| Tina M. Albertson | Chief Medical Officer | 69,589 | $28.90K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRBU quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.